These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32406275)

  • 1. Biologics and small molecules in patients with scalp psoriasis: a systematic review.
    Alsenaid A; Ezmerli M; Srour J; Heppt M; Illigens BM; Prinz JC
    J Dermatolog Treat; 2022 Feb; 33(1):473-482. PubMed ID: 32406275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations.
    Jo SJ; Huang YH; Tsai TF; Kim BS; Reich K; Saadoun C; Chang CL; Yang YW; Youn SW
    J Dermatol; 2023 Sep; 50(9):1180-1189. PubMed ID: 37341137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis.
    Huang IH; Wu PC; Chiu HY; Huang YH
    Am J Clin Dermatol; 2024 May; 25(3):347-358. PubMed ID: 38438782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
    Foley P; Gordon K; Griffiths CEM; Wasfi Y; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
    JAMA Dermatol; 2018 Jun; 154(6):676-683. PubMed ID: 29799960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
    Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
    J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
    Sawyer LM; Cornic L; Levin LÅ; Gibbons C; Møller AH; Jemec GB
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):355-366. PubMed ID: 30289198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Reich K; Leonardi C; Lebwohl M; Kerdel F; Okubo Y; Romiti R; Goldblum O; Dennehy EB; Kerr L; Sofen H
    J Dermatolog Treat; 2017 Jun; 28(4):282-287. PubMed ID: 27759463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study.
    Narcisi A; Valenti M; Cortese A; Toso F; Pavia G; Gargiulo L; Borroni R; Costanzo A
    Dermatol Ther; 2022 Feb; 35(2):e15228. PubMed ID: 34820969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Wade R; Grosso A; South E; Rothery C; Saramago P; Schmitt L; Wright K; Palmer S
    Pharmacoeconomics; 2019 Feb; 37(2):131-139. PubMed ID: 30112635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
    Warren RB; Gooderham M; Burge R; Zhu B; Amato D; Liu KH; Shrom D; Guo J; Brnabic A; Blauvelt A
    J Am Acad Dermatol; 2020 May; 82(5):1138-1149. PubMed ID: 31884091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis.
    Papp KA; Lebwohl MG
    J Drugs Dermatol; 2018 Mar; 17(3):247-250. PubMed ID: 29537442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
    J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis.
    Armstrong AW; Soliman AM; Betts KA; Wang Y; Gao Y; Puig L; Augustin M
    Dermatol Ther (Heidelb); 2021 Jun; 11(3):885-905. PubMed ID: 33788177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis.
    Xue W; Saharia P; Gray E; Khoudigian-Sinani S; Gaudet V; Barbeau M; Papp K
    J Cutan Med Surg; 2020; 24(6):561-572. PubMed ID: 32588642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans.
    Feldman SR; Wu JJ; Rastogi S; Menges B; Lingohr-Smith M; Lin J
    J Med Econ; 2018 May; 21(5):537-541. PubMed ID: 29357713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.